Richard A. Paulson - 28 Feb 2023 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
President and CEO, Director
Signature
/s/Nancy Smith as Attorney-in-Fact for Richard Paulson
Issuer symbol
KPTI
Transactions as of
28 Feb 2023
Net transactions value
-$100,064
Form type
4
Filing time
02 Mar 2023, 16:28:40 UTC
Previous filing
08 Feb 2023
Next filing
07 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +252,000 +42% $0.000000 856,655 28 Feb 2023 Direct F1
transaction KPTI Common Stock Sale $100,064 -33,033 -3.9% $3.03 823,622 01 Mar 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.
F2 This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.